Folate Receptor Alpha Peptide Vaccine With GM-CSF in Patients With Triple Negative Breast Cancer
Clinical trial NCT02593227 · COMPLETED
Trial details
- NCT number
- NCT02593227
- Sponsor
- Marker Therapeutics, Inc.
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2016-04-01
- Primary completion
- 2021-07-15
- Enrollment
- 80
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.